Abstract
The majority of patients diagnosed with chronic lymphocytic leukaemia (CLL) will ultimately die of their disease. Stem cell transplantation (SCT) remains the only treatment modality capable of cure, but has traditionally been associated with very high morbidity and mortality. We review the results of myeloablative autologous and allogeneic SCT in CLL, discuss the evolution of the new non-myeloablative approaches, and make recommendations for when SCT should be considered in patients with CLL.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 53-60 |
| Number of pages | 8 |
| Journal | Hematological Oncology |
| Volume | 27 |
| Issue number | 2 |
| DOIs | |
| State | Published - 2009 |
Keywords
- Alemtuzumab
- Bone marrow transplantation
- Reduced intensity conditioning
- Rituximab
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research